News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AVAX Technologies, Inc. (AVXT) to Present Results of Phase I-II Study of MVax(R) at 2008 Meeting of the American Society of Clinical Oncology



3/24/2008 9:29:40 AM

PHILADELPHIA--(BUSINESS WIRE)--AVAX Technologies, Inc. (OTC Market:AVXT.OB) announces that its abstract, entitled, “Dose-response study of a cryopreserved, autologous, hapten-modified melanoma vaccine (MVax®),” has been accepted for presentation at the annual meeting of the American Society for Clinical Oncology (ASCO) to be held May 30-June 3 in Chicago. The abstract was selected from the over 4,800 that were reviewed by ASCO’s Scientific Program Committee this year.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES